Internal Medicine, Medical Oncology · Atlanta, GA
NPI
1457326936
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1365 Clifton Rd NE, Winship Cancer Institute
Atlanta, GA, 30322
Phone (404) 778-5961
Groups this clinician bills Medicare through
Medicare paid, 2024
$5,227
71 services
Medicare patients, 2024
39
Average age 74
Drug cost, 2024
$2.0M
279 prescriptions
Company payments, 2025
$4,330
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Suresh S Ramalingam was code 99214 (office e&m - established), 56 times for 32 patients. In total Suresh S Ramalingam billed 71 services in 4 codes, and Medicare paid $5,227.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-11-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 56 | 32 | $70.19 | $3,931 |
By year: 2022 $6,532 for 89 services; 2023 $5,361 for 71 services; 2024 $5,227 for 71 services.
Medicare prescription drug claims, 2024
In 2024, the drug Suresh S Ramalingam prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 58 prescriptions and refills. In total Suresh S Ramalingam wrote 279 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 58 | 59 | Under 11 | $967K |
| Dexamethasone Generic | 38 | 39 | Under 11 | $250 |
| Retevmo Selpercatinib | 26 | 26 | Under 11 | $508K |
| Ondansetron Hcl Generic | 25 | 25 | Under 11 | $97.49 |
| Zykadia Ceritinib | 22 | 22 | Under 11 | $270K |
| Tabrecta Capmatinib Hydrochloride | 13 | 13 | Under 11 | $262K |
| Prochlorperazine Maleate Generic | 11 | 11 | Under 11 | $57.48 |
Brand drugs: 133 claims; generic drugs: 146 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Suresh S Ramalingam $4,330 ($1,240 in general payments such as food, travel and fees and $3,090 for research) from 10 companies. The largest payer was Pfizer Inc. with $3,090.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.